Getting your player ready...
Shares of Boulder-based Array Biopharma Inc., which is developing cancer drugs with AstraZeneca PLC, dropped $3.06, or 28 percent, to close at $7.96 on the Nasdaq Stock Market on Thursday, after a study showed its experimental treatment for skin cancer didn’t slow the disease.
The drug, AZD6244, was no more effective than chemotherapy in a study against advanced melanoma, Array reported in a statement Wednesday.
